licensing

News

GSK wagers $750m on Chimagen multiple myeloma therapy

GSK has continued a drive to bulk up its pipeline, taking global rights to a T-cell engager for multiple myeloma, developed by China's Chimagen Bio.

News

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

GSK has paid Hutchmed $110m upfront for rights to a preclinical KRAS and EGFR-directed drug with potential in colorectal, pancreatic, and lung cancer.

News

Roche taps Simcere for autoimmune trispecific for $1.53bn

Roche is paying $75m upfront for a trispecific drug developed by China's Simcere Zaiming for B-cell-mediated autoimmune disorders and blood cancers.

News

Sobi adds rare lymphoma drug with $580m Innate tie-up

Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.

News

UK's Mission divests kidney drug to Dimerix for $292m

Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.

News

Spero snaps up Innovent immunology drug in strategic pivot

Spero has licensed rights to an anti-CD40L antibody developed by China's Innovent, in a $1.1bn deal that signals a shift away from antimicrobial R&D.

GSK wagers $750m on Chimagen multiple myeloma therapy

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

Roche taps Simcere for autoimmune trispecific for $1.53bn

Sobi adds rare lymphoma drug with $580m Innate tie-up

UK's Mission divests kidney drug to Dimerix for $292m

Spero snaps up Innovent immunology drug in strategic pivot

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

licensing

Editor's Picks